Concepedia

Author

Daniel Maslyar

Tennessee Oncology

Also Known As

D J Maslyar, D. J. Maslyar, D. Maslyar, D.J. Maslyar, Daniel J Maslyar, Daniel J. Maslyar, Daniel Maslyar

78

Publications

2.8K

Citations

23

H-Index

59

Concepts

All Affiliations

Tennessee OncologySarah CannonInstitut Gustave RoussyMemorial Sloan Kettering Cancer CenterMassachusetts General Hospital
DM

About

Daniel Maslyar is an author at Tennessee Oncology specializing in medicine, oncology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

19

1.3K

2

Natural Sciences

5

5

413

3

Biology

2

2

184

4

Engineering

1

1

176

5

Biomolecular Engineering

1

1

176

Daniel Maslyar

×

31

Publications

2.7K

Citations

23

H-Index

YearCitations

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im,

The Lancet Oncology

2017

463

Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts

Thorsten Berg, Steven B. Cohen, Joel Desharnais,

Proceedings of the National Academy of Sciences

2002

323

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues,

Clinical Cancer Research

2018

303

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

James M. Burke, Donald L. Lamm, Maxwell V. Meng,

The Journal of Urology

2012

227

Novel and useful properties of a chimeric plant promoter combining CaMV 35S and MAS elements

Luca Comai, Paul Moran, Daniel Maslyar

Plant Molecular Biology

1990

176

Coordinate expression of transcriptionally regulated isocitrate lyase and malate synthase genes in Brassica napus L.

Lucio Comai, Robert Dietrich, Daniel Maslyar,

The Plant Cell

1989

132

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer,

Annals of Oncology

2016

132

Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad,

Molecular Cancer Therapeutics

2016

107

Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)

Ivan Borrello, Hyam I. Levitsky, Wendy Stock,

Blood

2009

97

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, C. Willemien Menke‐van der Houven van Oordt, Eva J. ter Weele,

Clinical Cancer Research

2015

96

Page 1